aleniglipron vs Ecnoglutide (VRB-101)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

aleniglipron

Developed by Structure Therapeutics

Phase 3 in Obesitysmall molecule
Partial signal

NCT06703021 · Phase 2 · completed

The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: September 2028 · NCT07654361 (registry estimate)

Reported efficacy

Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Baseline and week 44); Adverse events of special interest (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysis (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS duration (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperature (Baseline and week 44): Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) (not_applicable)

Result source: NCT06703021

Ecnoglutide (VRB-101)

Developed by Verdiva Bio under a licence from Sciwind Biosciences

Phase 2 in Obesitypeptide
Partial signal

NCT07281937 · Phase 2 · completed

The trial randomly assigns participants to VRB-101 or a matching placebo and keeps participants, care providers and assessors all blinded, using percent body weight change, a standard measure for obesity drugs, as its main result. Results have not been posted yet, so whether the weight-loss difference was statistically meaningful is not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Next expected readout: January 2027 · NCT07243171 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointaleniglipronEcnoglutide (VRB-101)
Body weight, % change—Trial running · NCT07654361—Not reported
Weight loss of 5% or more—Trial running · NCT07654361—Not reported
Weight loss of 10% or more—Trial running · NCT07654361—Not reported
Waist circumference, change (cm)—Trial running · NCT07654361—Not reported

Body weight, % change

aleniglipron
—Trial running · NCT07654361
Ecnoglutide (VRB-101)
—Not reported

Weight loss of 5% or more

aleniglipron
—Trial running · NCT07654361
Ecnoglutide (VRB-101)
—Not reported

Weight loss of 10% or more

aleniglipron
—Trial running · NCT07654361
Ecnoglutide (VRB-101)
—Not reported

Waist circumference, change (cm)

aleniglipron
—Trial running · NCT07654361
Ecnoglutide (VRB-101)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ecnoglutide (VRB-101): no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

aleniglipron
Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) NCT06703021 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · Ecnoglutide (VRB-101)'s landscape